CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

The 26-week PIONEER 5 trial is one of 10 clinical trials for oral semaglutide that are due to complete this year. Novo's oral semaglutide on target in phase 3 trial | pharmaphorum Skip to main content ...

The semaglutide trial showed effect sizes “in the medium to large range,” he said, although he urged caution about the results since the trial “was the first to look at this question in a ...

The human laboratory trial (NCT05520775), carried out by the University of North Carolina at Chapel Hill, US, saw nearly 40% of participants dosed with semaglutide report a reduction in their ...

Semaglutide may work quickly. In a 2021 clinical trial, some participants lost more than 2% of their body weight within 4 weeks. The weight loss pattern continued, and participants lost an average ...

Study: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder A Randomized Clinical Trial. Image Credit: simon jhuan/Shutterstock.com A recent JAMA Psychiatry study investigates the ...

Half received semaglutide, a type of GLP-1 receptor agonist, while the other half received no treatment. Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per ...

Semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with alcohol use ...